Virax Biolabs Group Ltd. Class A (VRAX) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Virax Biolabs Group Ltd. has partnered with French company Tebubio to distribute its ImmuneSelect portfolio across the European Union, Norway, and Switzerland. This collaboration aims to enhance the accessibility of ImmuneSelect products, which are crucial for researching adaptive immunity. The products, optimized for stimulating T cells, are intended for research use and not for diagnostic purposes.
For further insights into VRAX stock, check out TipRanks’ Stock Analysis page.